Showing results (101-110 of 369) with videos related to
Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2002
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castrationOren Smaletz, Howard I Scher, Eric J Small, et al.Cancer|May 27, 2003
The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancerAndrew J Roth, Barry Rosenfeld, Alice B Kornblith, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancerEthan M Basch, Mark R Somerfield, Tomasz M Beer, et al.European Urology|June 1, 2013
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literatureSanoj Punnen, Matthew R Cooperberg, Anthony V D'Amico, et al.Clinical Chemistry and Laboratory Medicine|June 22, 2012
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responsesDavid Ulmert, Andrew J Vickers, Howard I Scher, et al.European Urology|November 22, 2011
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancerAndrew J Armstrong, Mario A Eisenberger, Susan Halabi, et al.Cancer Journal (Sudbury, Mass.)|October 18, 2016
Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer PatientsDaniel C Danila, Aliaksandra Samoila, Chintan Patel, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 10, 2004
Decreased retinoid X receptor-alpha protein expression in basal cells occurs in the early stage of human prostate cancer developmentGloria E Mao, Victor E Reuter, Carlos Cordon-Cardo, et al.Clinical Genitourinary Cancer|February 15, 2020
A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate CancerDeaglan J McHugh, Jay Chudow, Mia DeNunzio, et al.The Lancet. Oncology|August 9, 2014
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trialKarim Fizazi, Howard I Scher, Kurt Miller, et al.Pageof 37